AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16238900 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 221
Study 16238900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 11838627 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (100 mg/day increasing to 400 mg/day over 4 weeks)
Number of subjects: 15
Study 11838627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10217596 — intervention group
Group type: EXPERIMENTAL
Intervention: PncCRM
Number of subjects: 0
Study 10217596 — intervention group
Group type: EXPERIMENTAL
Intervention: PncT
Number of subjects: 0
Study 10217596 — intervention group
Group type: EXPERIMENTAL
Intervention: PncD
Number of subjects: 0
Study 10217596 — intervention group
Group type: COMPARATOR
Intervention: PncOMPC
Number of subjects: 0
Study 7749155 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy of the remaining breast tissue
Number of subjects: 1036
Study 7749155 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1036
Study 2259863 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 7 days
Number of subjects: 52
Study 2259863 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 52
Study 7397630 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU, vinblastine, procarbazine, and prednisone (CVPP)
Number of subjects: 566
Study 7397630 — intervention group
Group type: COMPARATOR
Intervention: MVPP regimen (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 566
Study 7397630 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction regimens containing vinblastine
Number of subjects: 566
Study 7397630 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine with periodic reinforcement
Number of subjects: 566
Study 27352792 — intervention group
Group type: EXPERIMENTAL
Intervention: Make a Move intervention
Number of subjects: 177
Study 27352792 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 177
Study 28580654 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-window technique
Number of subjects: 21
Study 28580654 — intervention group
Group type: COMPARATOR
Intervention: Solo-window technique
Number of subjects: 21
Study 25920468 — intervention group
Group type: EXPERIMENTAL
Intervention: Church-based diabetes self-management program (eight weekly group classes led by trained lay leaders)
Number of subjects: 100
Study 25920468 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (one 90-minute lecture on diabetes self-management)
Number of subjects: 100
Study 23630211 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF throughout all chemotherapy cycles
Number of subjects: 167
Study 23630211 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF during the first two cycles only
Number of subjects: 167
Study 21271228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 56
Study 21271228 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation (NSt)
Number of subjects: 56
Study 19058889 — intervention group
Group type: EXPERIMENTAL
Intervention: S3 Bond (S3)
Number of subjects: 23
Study 19058889 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bond (GB)
Number of subjects: 23
Study 17695603 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (HP) concentrations ranging from 15% to 35% with treatment contact times of 15 to 60 minutes.
Number of subjects: 8
Study 15096085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (50‐400 mg/day fixed dose or 100‐400 mg/day flexible dose)
Number of subjects: 638
Study 15096085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (serum level of 0.8‐1.1 mEq/L)
Number of subjects: 638
Study 15096085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 638
Study 15096085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 638
Study 15096085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 638
Study 12017403 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 50 mg alone
Number of subjects: 24
Study 12017403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Sumatriptan 50 mg + Clarithromycin 500 mg)
Number of subjects: 24
Study 12017403 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Sumatriptan alone and Combination treatment)
Number of subjects: 24
Study 10191737 — intervention group
Group type: EXPERIMENTAL
Intervention: Norian SRS (injectable calcium phosphate bone cement)
Number of subjects: 40
Study 10191737 — intervention group
Group type: COMPARATOR
Intervention: External fixation (Hoffman's bar)
Number of subjects: 40
Study 7741372 — intervention group
Group type: EXPERIMENTAL
Intervention: Early zidovudine therapy
Number of subjects: 0
Study 7741372 — intervention group
Group type: COMPARATOR
Intervention: Deferred zidovudine therapy
Number of subjects: 0
Study 2373130 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy deficient diet (daily energy intake 4.3 MJ; daily protein intake 0.94 g/kg)
Number of subjects: 9
Study 2373130 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein deficient diet (daily energy intake 11.4 MJ; daily protein intake 0.31 g/kg)
Number of subjects: 9
Study 2373130 — intervention group
Group type: COMPARATOR
Intervention: Control diet (daily energy intake 12.0 MJ; daily protein intake 1.52 g/kg)
Number of subjects: 9
Study 7032558 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine tablets (MST-1; 2 x 10 mg)
Number of subjects: 28
Study 7032558 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine sulphate in solution (20 mg)
Number of subjects: 28
Study 7032558 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine tablets (MST-1)
Number of subjects: 28
Study 31508861 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop
Number of subjects: 32
Study 31508861 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision-consultation
Number of subjects: 32
Study 31508861 — intervention group
Group type: EXPERIMENTAL
Intervention: External facilitation
Number of subjects: 32
Study 29882677 — intervention group
Group type: EXPERIMENTAL
Intervention: app + meter
Number of subjects: 44
Study 29882677 — intervention group
Group type: COMPARATOR
Intervention: meter-only
Number of subjects: 44
Study 27107155 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0
Study 25196040 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-glucose combination (60g glucose + 40mg caffeine)
Number of subjects: 150
Study 25196040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 25196040 — intervention group
Group type: COMPARATOR
Intervention: 60g glucose
Number of subjects: 150
Study 25196040 — intervention group
Group type: COMPARATOR
Intervention: 25g glucose
Number of subjects: 150
Study 22120913 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy (deferasirox)
Number of subjects: 161
Study 22120913 — intervention group
Group type: COMPARATOR
Intervention: Chronic transfusion therapy
Number of subjects: 161
Study 22120913 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of iron burden
Number of subjects: 161
Study 21194441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular interleukin-1 receptor antagonist (IL-1Ra) therapy
Number of subjects: 11
Study 17428721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioselective beta-blockers
Number of subjects: 40
Study 17428721 — intervention group
Group type: COMPARATOR
Intervention: No beta-blockers (Control)
Number of subjects: 40
Study 16334760 — intervention group
Group type: EXPERIMENTAL
Intervention: CT colonography
Number of subjects: 32
Study 16334760 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 32
Study 12488789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabry patients
Number of subjects: 30
Study 9498410 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST performed by surgery residents or attending trauma surgeons
Number of subjects: 196
Study 9498410 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST performed in a mean time of 3.9 minutes
Number of subjects: 196
Study 9498410 — intervention group
Group type: COMPARATOR
Intervention: Patients followed up clinically without CT or surgery
Number of subjects: 196
Study 8060251 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (SC 0.87 ± 0.10)
Number of subjects: 10
Study 8060251 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (DC 0.74 ± 0.06)
Number of subjects: 10
Study 8060251 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (SC 1.01 ± 0.04)
Number of subjects: 10
Study 8060251 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (DC 0.97 ± 0.04)
Number of subjects: 10
Study 8060251 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (SC 1.01 ± 0.05)
Number of subjects: 10
Study 8060251 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (DC 1.01 ± 0.07)
Number of subjects: 10
Study 8060251 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (SC 1.00 ± 0.09)
Number of subjects: 10
Study 8060251 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (DC 1.01 ± 0.06)
Number of subjects: 10
Study 2564723 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin monotherapy
Number of subjects: 194
Study 2564723 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyclothiazide (MCTZ) monotherapy
Number of subjects: 194
Study 2564723 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin/MCTZ combination therapy
Number of subjects: 194
Study 2564723 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy vs. monotherapy
Number of subjects: 194
Study 28058491 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomethylating therapy with decitabine
Number of subjects: 87
Study 26248593 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg for 7 days)
Number of subjects: 2
Study 26248593 — intervention group
Group type: COMPARATOR
Intervention: Simeprevir (200 mg single dose)
Number of subjects: 2
Study 26248593 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir
Number of subjects: 2
Study 24051622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (SEQ) with chemical nail avulsion, RV4104A ointment (40% urea), ciclopirox cream for 8 weeks, and ciclopirox nail lacquer for 25 weeks
Number of subjects: 142
Study 24051622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (SEQ)
Number of subjects: 142
Study 24051622 — intervention group
Group type: COMPARATOR
Intervention: Amorolfine nail lacquer
Number of subjects: 142
Study 20444308 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg/kg) followed by lactate (10 mg/kg)
Number of subjects: 25
Study 20444308 — intervention group
Group type: COMPARATOR
Intervention: Saline followed by lactate
Number of subjects: 25
Study 18314474 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored and targeted intervention
Number of subjects: 0
Study 18314474 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted-only intervention
Number of subjects: 0
Study 18314474 — intervention group
Group type: COMPARATOR
Intervention: Survey-only control group
Number of subjects: 0
Study 17036484 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong acupuncture intensity
Number of subjects: 80
Study 17036484 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate acupuncture intensity
Number of subjects: 80
Study 17036484 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak acupuncture intensity
Number of subjects: 80
Study 17036484 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycemic drug (control group)
Number of subjects: 80
Study 17036484 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture groups (strong, moderate, weak)
Number of subjects: 80
Study 17036484 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral hypoglycemic drug)
Number of subjects: 80
Study 14743961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 80 mg/day for 8 weeks
Number of subjects: 62
Study 14743961 — intervention group
Group type: COMPARATOR
Intervention: Normocholesterolaemic controls
Number of subjects: 62
Study 14743961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 62
Study 10719694 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Treatment Position (CTP)
Number of subjects: 30
Study 10719694 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilisation System (IMS)
Number of subjects: 30
Study 8732493 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, euglycaemic clamp (1 mu kg‐1 min‐1, 5 mmol L‐1)
Number of subjects: 12
Study 8732493 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 8732493 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic clamp
Number of subjects: 12
Study 7904767 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol 400 micrograms q.i.d. for 4 weeks
Number of subjects: 48
Study 7904767 — intervention group
Group type: COMPARATOR
Intervention: Sodium chromoglycate 10 mg q.i.d. for 4 weeks (control)
Number of subjects: 48
Study 3554492 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision followed by fistulotomy
Number of subjects: 38
Study 3554492 — intervention group
Group type: COMPARATOR
Intervention: Incision only
Number of subjects: 38
Study 29633646 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
Number of subjects: 108
Study 29633646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 27440671 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS (1.5 mg/ml; total dose 4.2 mg)
Number of subjects: 24
Study 27440671 — intervention group
Group type: COMPARATOR
Intervention: ABG (autogenous bone graft)
Number of subjects: 24
Study 27440671 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 24
Study 27440671 — intervention group
Group type: COMPARATOR
Intervention: ABG
Number of subjects: 24
Study 25825539 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider + RD (Group 3) - delivered 4 MI sessions from providers plus 6 MI sessions from a registered dietitian.
Number of subjects: 42
Study 25825539 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider only (Group 2) - delivered 4 MI counseling sessions to parents over 2 years.
Number of subjects: 42
Study 25825539 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Group 1) - measured BMI percentile at baseline and 1- and 2-year follow-up.
Number of subjects: 42
Study 23512651 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 389
Study 23512651 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-phone text message reminders
Number of subjects: 389
Study 23512651 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call reminders
Number of subjects: 389
Study 23512651 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction score increase
Number of subjects: 389
Study 23512651 — intervention group
Group type: EXPERIMENTAL
Intervention: High patient satisfaction with reminders
Number of subjects: 389
Study 23512651 — intervention group
Group type: EXPERIMENTAL
Intervention: General feelings about reminders
Number of subjects: 389
Study 23512651 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement on reminders enhancing intention to revisit
Number of subjects: 389
Study 23512651 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for continued reminders
Number of subjects: 389
Study 22105509 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 0.45%
Number of subjects: 121
Study 22105509 — intervention group
Group type: EXPERIMENTAL
Intervention: bromfenac 0.09%
Number of subjects: 121
Study 22105509 — intervention group
Group type: EXPERIMENTAL
Intervention: nepafenac 0.1%
Number of subjects: 121
Study 19255911 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalisation during task performance
Number of subjects: 22
Study 19255911 — intervention group
Group type: COMPARATOR
Intervention: Silence during task performance
Number of subjects: 22
Study 16217841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomization of continuous predictor variables
Number of subjects: 0
Study 16217841 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-derived 'optimal' cutpoint
Number of subjects: 0
Study 16217841 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis without dichotomization
Number of subjects: 0
Study 12715124 — intervention group
Group type: EXPERIMENTAL
Intervention: BTAstat test
Number of subjects: 115
Study 12715124 — intervention group
Group type: EXPERIMENTAL
Intervention: NMP 22 test
Number of subjects: 115
Study 12715124 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytology with 486p3/12
Number of subjects: 115
Study 12715124 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytology with Lewis X
Number of subjects: 115
Study 10687882 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 Matrix 0.10 mg
Number of subjects: 254
Study 10687882 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 Matrix 0.05 mg
Number of subjects: 254
Study 10687882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 9377886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water (HW) circuit with a 2‐day circuit change (n = 41)
Number of subjects: 116
Study 9377886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial‐viral filtering HME with a 2‐day circuit change (n = 42)
Number of subjects: 116
Study 9377886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial‐viral filtering HME with a 4‐day circuit change (n = 33)
Number of subjects: 116
Study 9377886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial‐viral filtering HME (2-day change)
Number of subjects: 116
Study 9377886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial‐viral filtering HME (4-day change)
Number of subjects: 116
Study 9377886 — intervention group
Group type: EXPERIMENTAL
Intervention: HME use
Number of subjects: 116
Study 9377886 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 116
Study 9377886 — intervention group
Group type: EXPERIMENTAL
Intervention: HME
Number of subjects: 116
Study 8440761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (25 mL in 150 mL of grapefruit juice)
Number of subjects: 4
Study 3532535 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy with diethylstilbestrol
Number of subjects: 118
Study 3532535 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy with tamoxifen
Number of subjects: 118
Study 3532535 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 118
Study 28632529 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP (12 cm H2O)
Number of subjects: 36
Study 28632529 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP (0-2 cm H2O)
Number of subjects: 36
Study 29939700 — intervention group
Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip (PFT) endotracheal tube
Number of subjects: 100
Study 29939700 — intervention group
Group type: COMPARATOR
Intervention: Preformed Nasal (PNT) tube
Number of subjects: 100
Study 25380842 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sequential treatment (Group A: local chemotherapeutic drug injection with ordinary metal stent implantation)
Number of subjects: 240
Study 25380842 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sequential treatment (Group B: local chemotherapeutic drug injection with iodine‐125 particle implantation)
Number of subjects: 240
Study 25380842 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sequential treatment (Group C: radiofrequency therapy with ordinary metal stent)
Number of subjects: 240
Study 25380842 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (Group D: local chemotherapeutic drug injection)
Number of subjects: 240
Study 25380842 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (Group E: RF therapy)
Number of subjects: 240
Study 25380842 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (Group F: common metal stent implantation)
Number of subjects: 240
Study 22008715 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with SLA surface
Number of subjects: 24
Study 19936863 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP (Computed Tomography Perfusion)
Number of subjects: 47
Study 19936863 — intervention group
Group type: COMPARATOR
Intervention: SPECT-MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
Number of subjects: 47
Study 18692203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 35
Study 18692203 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 35
Study 15784070 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-related stimuli (denicotinized cigarettes)
Number of subjects: 32
Study 15784070 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nicotine and smoking-related stimuli
Number of subjects: 32
Study 12792123 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medications
Number of subjects: 0
Study 10590363 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin-CDE (PCDE)
Number of subjects: 457
Study 10590363 — intervention group
Group type: COMPARATOR
Intervention: CDE
Number of subjects: 457
Study 8687199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide 25 mg/day
Number of subjects: 321
Study 8687199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide 50 mg/day
Number of subjects: 321
Study 8687199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide 100 mg/day
Number of subjects: 321
Study 8687199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide 200 mg/day
Number of subjects: 321
Study 8687199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 1531994 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide, 1.6 mg daily for 3 weeks
Number of subjects: 12
Study 1531994 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, 40 mg daily for 8 days
Number of subjects: 12
Study 1531994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12